I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
View All Publications
A New Way to Treat Ischemic Stroke
When the use of tissue plasminogen activator (tPA) was approved by the U.S. Food and Drug Administration in 1996, it was a watershed moment for stroke treatment. Many ischemic stroke patients who were destined for a lifetime of extreme disability or death often went on to live productive lives. However, notes neurologist and director of The Johns Hopkins Hospital’s Stroke Center Victor Urrutia, tPA was an imperfect fix. When clots were lodged within the brain’s larger arteries, or when significant time had passed, tPA isn’t as effective.
However, new tools approved for use just three years ago could make the difference for patients when tPA doesn’t. These devices, known as stentrievers, mechanically remove blood clots from the brain, providing a way to reopen arteries even when stubborn clots don’t respond fully to tPA. Recent studies published in the New England Journal of Medicine showed that combining the use of stentrievers with tPA can increase the number of people living independently three months after stroke from 30 percent to nearly 70 percent.
“These are dramatic numbers of people helped with this new technology,” says Johns Hopkins endovascular neurosurgeon Alexander Coon, who uses stentrievers in combination with tPA routinely in his practice.
The new devices are basically “stents on a stick” that open within a clot, explains Johns Hopkins neurosurgeon Geoffrey Colby. By threading the collapsed chicken-wirelike stent into a clot with a wire, then opening it, these devices interdigitate the clot’s gelatinous material, allowing surgeons to easily grab it and remove even large clots buried deep within the brain. Blood flow is instantly restored, leading to less ischemic damage and, thus, better function for patients over time.
“Now, any patient who receives tPA could potentially be a candidate for these other therapies if they have a large order occlusion and don’t show signs of an already concluded stroke in imaging,” Colby says.
Because of the specialized nature of this therapy, Urrutia adds, it’s mostly offered at certified Comprehensive Stroke Centers, such as The Johns Hopkins Hospital. These centers, numbering around 80 in the country, have the necessary concentration of experts and tools to effectively and safely deliver this therapy. For this reason, Urrutia says, he and colleagues across the nation are leading efforts to modify routing protocols for ambulances to deliver suspected stroke patients to Comprehensive Stroke Centers, even if they have to bypass other hospitals.
With the very clear and enormous success combining these stentrievers with tPA, it’s clear that this treatment protocol is here to stay and has the promise of helping untold numbers of patients who wouldn’t benefit from tPA alone.
“Just as tPA changed the way we take care of stroke in 1996,” Urrutia says, “endovascular therapy is leading to an exciting new era.”